31 Mar 2023
Assets420.11
Total Income438.26
EBITDA98.64
Profit After Tax62.32
NET Worth226.29
Reserves and Surplus221.88
Total Borrowing82.26
At a glance
Updated 2026-09-10The shares listed at ₹730.00, a 23.10% move from the issue price. Sudeep Pharma is a Mainboard IPO with an issue size of ₹895.00 crore, proposed for listing on BSE, NSE. The offer opens on 21st Nov 2025 and closes on 25th Nov 2025. The issue structure includes a fresh issue of ₹95.00 crore and an offer-for-sale component of ₹800.00 crore. The current listing schedule points to 28th Nov 2025.
Issue details
Listing atBSE, NSE
Issue typeBook Build Issue
Issue size₹895.00 Cr
Fresh issue₹95.00 Cr
Offer for sale₹800.00 Cr
Face value₹1
Price band₹563.00–₹593.00
Allotment26th Nov 2025
Listing28th Nov 2025
Listing performance
Full performance ↗Issue price₹593.00
Listing price₹730.00
Current price—
Listing gain23.10%
Current return—
Price progressionIssue → Listing → Current
Grey market
GMP page ↗Latest GMP₹121.00
GMP / upper price20.40%
Est. listing₹714.00
GMP is unofficial sentiment data, not an exchange price.
Timeline
Opens21st Nov 2025
Closes25th Nov 2025
Allotment26th Nov 2025
Refund27th Nov 2025
Demat27th Nov 2025
Listing28th Nov 2025
Subscription demand
Full bidding ↗QIB213.08×
sHNI78.85×
bHNI134.91×
NII / HNI134.91×
Retail14.59×
Total93.71×
Lot size
| Investor | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 25 | ₹14,825 |
| Retail (Max) | 13 | 325 | ₹192,725 |
| S-HNI (Min) | 14 | 350 | ₹207,550 |
| S-HNI (Max) | 67 | 1675 | ₹993,275 |
| B-HNI (Min) | 68 | 1700 | ₹1,008,100 |
Company
Incorporated1989
Use of proceeds
| Object | Amount |
|---|---|
| Capital expenditure towards procurement of machinery for the production line located at Nandesari Facility I | ₹75.81 Cr |
| General Corporate Purposes | ₹12.67 Cr |
| Issue Expenses | ₹61.97 Cr |
| Total | ₹150.45 Cr |
Financial performance
Year-wise operating scale, profitability and balance-sheet context.Revenue130.08₹ Cr · -74.6% vs prior year
EBITDA48.57₹ Cr · -75.6% vs prior year
PAT31.27₹ Cr · -77.5% vs prior year
Assets922.26₹ Cr · +28.6% vs prior year
Net Worth688.32₹ Cr · +38.3% vs prior year
Borrowing135.97₹ Cr · +0.5% vs prior year
3-year financial trendRevenue / EBITDA / PAT
₹ crore31 Mar 2024
Assets513.87
Total Income465.38
EBITDA187.76
Profit After Tax133.15
NET Worth359.07
Reserves and Surplus354.59
Total Borrowing75.03
31 Mar 2025
Assets717.17
Total Income511.33
EBITDA199.28
Profit After Tax138.69
NET Worth497.53
Reserves and Surplus481.11
Total Borrowing135.25
30 Jun 2025
Assets922.26
Total Income130.08
EBITDA48.57
Profit After Tax31.27
NET Worth688.32
Reserves and Surplus668.52
Total Borrowing135.97
KPIs
| KPI | Mar 31, 2025 |
|---|---|
| Debt / Equity | 0.20% |
| RoNW | 27.88% |
| PAT Margin | 27.63% |
| EBITDA Margin | 39.70% |
| Price to Book Value | 12.93 |
Valuation & shareholding
Pre-IPO EPS12.46
Post-IPO EPS11.07
Pre-IPO P/E47.61
Post-IPO P/E53.55
Promoter holding pre89.37%
Promoter holding post76.15%
Market cap₹6697.85 Cr.
Peer comparison
| Company | EPS | P/E | RoNW | NAV |
|---|---|---|---|---|
| Sudeep Pharma IPO | — | 53.55 x | — | — |
| Symbiotec Pharmalab IPO | — | 61.88 x | — | — |
| Sai Parenteral's IPO | — | 111.58 x | — | — |
| Corona Remedies IPO | — | 35.15 x | — | — |
Issue expenses
| Expense | Amount |
|---|---|
| Capital expenditure towards procurement of machinery for the production line located at Nandesari Facility I | ₹75.81 Cr |
| General Corporate Purposes | ₹12.67 Cr |
| Issue Expenses | ₹61.97 Cr |
| Total | ₹150.45 Cr |
Registrar & lead managers
Registrar
MUFG Intime India Pvt.Ltd.Lead managers
- ICICI Securities Ltd.
Offer documents
Data is reconciled from multiple public IPO sources. Official exchange filings and offer documents remain the source of truth. Last verified 2026-09-10.
IPO UPDATE ALERTS
Register for IPO Updates →Track Sudeep Pharma without missing an update
Register for subscription, GMP, allotment and listing notifications.